THE EFFECTIVENESS OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM IN INCREASING INSULIN SENSITIVITY, REDUCING THE RISK OF DEVELOPING DIABETES, LIVER OBESITY, LIVER FIBROSIS

Authors

  • Kravchenko N. A. GI «L. T. Malaya Therapy National Institute of the NAMS of Ukraine», Kharkiv, Ukraine
  • Voitenko E. I. GI «L. T. Malaya Therapy National Institute of the NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2011.3.13

Keywords:

diabetes mellitus, angiotensin, fatty liver disease, insulin

Abstract

Angiotensin II acts as a promoter of cardiovascular disorders, renal pathology, plays a role in potentiating known risk factors: hypertension, hyperlipidemia, insulin resistance, inflammation. ATII can weaken intracellular insulin signals, which leads to a decrease in muscle glucose uptake, suppression of adipocyte differentiation.

References

Insulin resistance and hypertention. The insulin resistence atherosclerosis study [Text] / M. F. Saad, M. Rewers, J. Selby [et al.] // Hypertention. — 2004. — Vol. 43, № 6. — P. 1324–1331.

Angiotensin II stimulates the release of interleukin6 and interleukin-8 from cultured human adipocytes by activation of NF-kB. [Text] / T. Skurk, van V. Harmelen, H. Hauner // Arterioscler Thromb Vasc Biol. — 2004. — Vol. 24. — P. 1199–1203.

Sharma, A. M. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? [Text] / A. M. Sharma // Int. J.

Biochem. — Cell. Biol. — 2003. — Vol. 35. — P. 807–825.

Angiotensin II as a trophic factor of white adipose tissue: Stimulation of adipose cell formation. [Text] / P. Saint-Marc, L. P. Kozak, G. Ailhaud [et al.] // Endocrinology. — 2001. — Vol. 142. — P. 487– 492.

Machado, M. Non-alcoholic fatty liver disease and insulin resistance. [Text] / M. Machado, H. Cortez98 Pinto // Europ. J. Gastroenterol. Hepatol. — 2005. — Vol. 17. — P. 823–826.

Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. [Text] / L. A. Cassis, V. L. English, K. Bharadwaj, C. M. Boustany // Endocrinology. — 2004. — Vol. 145. — P. 169–174.

Molecular mediators of hepatic steatosis and liver injury [Text] / D. Jeffrey, J. Browning, D. Horton // Clin. Invest. — 2004. — Vol. 114, № 2. — P. 147–152.

Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat [Text] / T. M. Wallace, K. M. Utzsecneider, G. Tong [et al.] // Diabetes Care. — 2007. — Vol. 30. — P. 2673–2678.

Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. [Text] / G. Musso, R. Gambino, S. Bo [et al.] // Diabetes Care. — 2008. — Vol. 31. — P. 562–568.

Ran, J. Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats [Text] / J. Ran, T. Hirano, M. Adachi // J. Hypertens. — 2005. — Vol. 23. — P. 1525–1530.

Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. [Text] / G. Targher, L. Bertolini, R. Padovani [et al.] // Diabetes Care. — 2006. — Vol. 29. — P. 1325–1330.

Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet [Text] / K. Kawaguchi, I. Sakaida, M. Tsuchiya [et al.] // Biochem. Biophys. Res. Commun. — 2004. — Vol. 315. — P. 187–95.

Long-term Angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARγ [Text] / S. Zorad, Jing-tao Dou1, J. Benicky [et al.] // Europ. J. Pharmacol. — 2006. — Vol. 15, № 552

(1–3). — P. 112–122.

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. [Text] / T. Kadowaki, T. Yamauchi, N. Kubota [et al.] // J. Clin. Invest. — 2006. — Vol. 116. — P. 1784–1792.

Scheen, A. J. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system [Text] / A. J. Scheen // Drugs. — 2004. — Vol. 64, № 22. — P. 2537–2565.

Takeuchi, M. Telmisartan is a promising cardiometabolic sartan due to its unique PPARgamma-inducing property. [Text] / M. Takeuchi

// Med. Hypotheses. — 2005. — Vol. 64, № 3. — P. 476–478.

Molecular characterization of new selective peroxisome proliferator activated receptor γ modulations with angiotensin receptor blocking activity [Text] / M. Schupp, M. Clemenz, R. Gineste // Diabetes. — 2005. — Vol. 54. — P. 3442–3452.

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [Text] / E. J. Lewis, L. G. Hunsicker, W. R. Clarke [et al.] // N. Engl. J. Med. — 2001. — Vol. 345. — P. 851–860.

PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin. [Text] / R. Clasen, M. Schupp, A. Foryst-Ludwig [et al.] // Hypertension. — 2005. — Vol. 46. — P. 137–143.

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARf×-modulating activity [Text] / S. C. Benson, H. A. Pershadsingh, C. I. Ho [et al.] // Hypertension. — 2004. — Vol. 43. — P. 993–1002.

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity [Text] / M. Schupp, J. Janke, R. Clasen [et al.] // Circulation. — 2004. — Vol. 109. — P. 2054–2057.

Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha [Text] / I. A. Arenas, Y. Xu, P. Lopez-Jaramillo,

S. T. Davidge // Am. J. Physiol.Cell. Physiol. — 2004. — Vol. 286. — P. C779–C784.

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease [Text] / B. Schieffer, C. Bunte, J. Witte [et al.] // J. Am. Coll. Cardiol. — 2004. — Vol. 44. — P. 362–368.

Why blockade of renin-angiotensin system reduces the incidence of new-onset diabetes [Text] / K. A. Jandeleit-Dahm, C. Tikellis, C. M. Reid [et al.] // J. Hypertens. — 2005. — Vol. 23. — P. 463–473.

Unger, T. Targeting Cardiovascular Protection: The Concept of Dual Renin-Angiotensin System Control. [Text] / T. Unger // Medscape J. Med. — 2008. — Vol. 10 (Supp). — P. S4.

An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells [Text] / N. Kurikawa, M. Suga, S. Kuroda [et al.] // British

J. Pharmacol. — 2003. — Vol. 139. — P. 1085–1094.

Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats [Text] / K. Okada, T. Hirano, J. Ran, M. Adachi // Hypertens Res. — 2004. — Vol. 27. — P. 293–299.

Yoshiji, H. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats [Text] / H. Yoshiji // J. Hepatol.. — 2002. — Vol. 37. — P. 22–30.

Wei, H. S. The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CCl(4) [Text] / H. S. Wei // World J. Gastroenterol. — 2000. — Vol. 6. — P. 824–828.

Bataller, R. Angiotensin II induces contraction and proliferation of human hepatic stellate cells [Text] / R. Bataller // Gastroenterology. — 2000. — Vol. 118. — P. 1149–1156.

Downloads

Published

2011-09-27

How to Cite

Kravchenko, N. A., & Voitenko, E. I. (2011). THE EFFECTIVENESS OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM IN INCREASING INSULIN SENSITIVITY, REDUCING THE RISK OF DEVELOPING DIABETES, LIVER OBESITY, LIVER FIBROSIS. Problems of Endocrine Pathology, 37(3), 95-100. https://doi.org/10.21856/j-PEP.2011.3.13